|
|
|
Volumn 24, Issue 3 SUPPL. 8, 1997, Pages
|
|
Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CAMPTOTHECIN;
CISPLATIN;
DNA TOPOISOMERASE INHIBITOR;
DOCETAXEL;
GEMCITABINE;
IFOSFAMIDE;
MITOMYCIN;
TOPOTECAN;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
MIP PROTOCOL;
RIBONUCLEOTIDE REDUCTASE;
ADULT;
ADVANCED CANCER;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
FEMALE;
HUMAN;
ITALY;
LUNG NON SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
MALE;
META ANALYSIS;
MINIMUM INHIBITORY CONCENTRATION;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
SURVIVAL RATE;
TREATMENT PLANNING;
AGED;
ARTICLE;
COMPARATIVE STUDY;
DRUG ANTAGONISM;
LUNG TUMOR;
MULTICENTER STUDY;
RANDOMIZED CONTROLLED TRIAL;
AGED;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, NON-SMALL-CELL LUNG;
CISPLATIN;
DEOXYCYTIDINE;
HUMANS;
IFOSFAMIDE;
LUNG NEOPLASMS;
MITOMYCIN;
RIBONUCLEOTIDE REDUCTASES;
|
|
EID: 0030925738
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (8)
|
|
References (19)
|
